Systemic vasculitis and headache.
Journal
Current opinion in neurology
ISSN: 1473-6551
Titre abrégé: Curr Opin Neurol
Pays: England
ID NLM: 9319162
Informations de publication
Date de publication:
01 Dec 2023
01 Dec 2023
Historique:
medline:
20
11
2023
pubmed:
22
10
2023
entrez:
22
10
2023
Statut:
ppublish
Résumé
Vasculitis refers to heterogeneous clinicopathologic disorders that share the histopathology of inflammation of blood vessels. Unrecognized and therefore untreated, vasculitis of the nervous system or so called neurovasculitides, lead to pervasive injury and disability making these disorder of paramount importance to clinicians. Headache is an important clue to vasculitic involvement of central nervous system (CNS) vessels. CNS vasculitis may be primary, in which only intracranial vessels are involved in the inflammatory process, or secondary to another known disorder with overlapping systemic involvement. A suspicion of vasculitis based on the history, clinical examination, or laboratory studies warrants prompt evaluation and treatment to forestall progression and avert cerebral ischemia or infarction. There has been remarkable progress in the pathogenesis, diagnosis, and treatment of primary adult and pediatric CNS vasculitides predicated on achievements in primary systemic forms. Vasculitis can be diagnosed with certainty after intensive evaluation that includes tissue confirmation whenever possible. Clinicians must choose from among the available immune modulating, suppressive, and targeted immunotherapies to induce and maintain remission status and prevent relapse, tempered by the recognition of anticipated medication side effects.
Identifiants
pubmed: 37865837
doi: 10.1097/WCO.0000000000001223
pii: 00019052-990000000-00118
pmc: PMC10624412
doi:
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
631-646Informations de copyright
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.
Références
Harbitz F. Unknown forms of arteritis with special reference to their relation to syphilitic arteritis and periarteritis nodosa. Am J Med Sci 1922; 163:250–272.
Kussmaul A, Maier R. Ueber eine bisher nicht beschriebene eigenthümliche arterienerkrankung (periarteritis nodosa), die mit morbus brightii und rapid fortschreitender allgemeiner muskellähmung einhergeht. Deutsche Arch klin Med 1866; 1:484–551.
Younger DS. Vasculitis of the nervous system. Curr Opin Neurol 2004; 17:317–336.
Younger DS. Adult and childhood vasculitis. Chapter 28. In, DS Younger, Ed. Motor system disorders. Part I: normal physiology and function and neuromuscular disorders. Handb Clin Neurol 2023; 195:653–704.
Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013; 65:1–11.
Ozen S, Ruperto N, Dillon MJ, et al. EULAR/PRES endorsed consensus criteria for the classification of childhood vasculitides. Ann Rheum Dis 2006; 65:936–941.
Ruperto N, Ozen S, Pistorio A, et al. EULAR/PRINTO/PRES criteria for Henoch-Schonlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part I: Overall methodology and clinical characterisation. Ann Rheum Dis 2010; 69:790–797.
Ozen S, Pistorio A, Iusan SM, et al. Paediatric Rheumatology International Trials Organization (PRINTO). EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: final classification criteria. Ann Rheum Dis 2010; 69:798–806.
Blair RJ, Ross JJ, Morris A, et al. A sleeping giant. N Engl J Med 2011; 365:72–77.
Hunder GG, Bloch DA, Michel BA, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 1990; 33:1122–1128.
Blockmans D, Bley T, Schmidt W. Imaging for large-vessel vasculitis. Curr Opin Rheumatol 2009; 21:19–28.
Salvarani C, Cantini F, Boiardi L, et al. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med 2002; 347:261–271.
Nakao K, Ikeda M, Kimata SI, et al. Takayasu's arteritis: clinical report of eighty-four cases and immunologic studies of seven cases. Circulation 1967; 35:1141–1155.
Riehl JL, Brown J, et al. Takayasu's disease. Arch Neurol 1965; 12:92–97.
Kerr GS, Hallahan CW, Giordano J, et al. Takayasu arteritis. Ann Intern Med 1994; 120:919–929.
Graham JR. Migraine (clinical aspects). Handb Clin Neurol 1968; 5:45–58.
Manno RL, Levine SM, Gelber AC. More than meets the eye. Semin Arthritis Rheum 2011; 40:324–329.
Arend WP, Michel BA, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum 1990; 33:1129–1134.
Grayson PC, Maksimowicz-McKinnon K, Clark TM, et al. Distribution of arterial lesions in Takayasu's arteritis and giant cell arteritis. Ann Rheum Dis 2012; 71:1329–1334.
Walker DI, Bloor K, Williams G, et al. Inflammatory aneurysms of the abdominal aorta. Br J Surg 1972; 59:609–614.
Sakata N, Tashiro T, Uesugi N, et al. IgG4-positive plasma cells in inflammatory abdominal aortic aneurysm: the possibility of an aortic manifestation of IgG4-related sclerosing disease. Am J Surg Pathol 2008; 32:553–559.
Kasashima S, Zen Y, Kawashima A, et al. Inflammatory abdominal aortic aneurysm: close relationship to IgG4-related periaortitis. Am J Surg Pathol 2008; 32:197–204.
Ito H, Kaizaki Y, Noda Y, et al. IgG4-related inflammatory abdominal aortic aneurysm associated with autoimmune pancreatitis. Pathol Int 2008; 58:421–426.
Stone JR. Aortitis, periaortitis, and retroperitoneal fibrosis, as manifestations of IgG4-related systemic disease. Curr Opin Rheumatol 2011; 23:88–94.
Pipitone N, Salvarani C. Idiopathic aortitis: an underrecognized vasculitis. Arthritis Res Ther 2011; 13:119.
Gornik HL, Creager MA. Aortitis. Circulation 2008; 117:3039–3051.
Stone JH, Khosroshahi A, Deshpande V, et al. IgG4-related systemic disease accounts for a significant proportion of thoracic lymphoplasmacytic aortitis cases. Arthritis Care Res 2010; 62:316–322.
Kernohan JW, Woltman HW. Periarteritis nodosa: a clinicopathologic study with special reference to the nervous system. Arch Neurol 1938; 39:655–686.
Kawasaki T. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children. Arerugi 1967; 16:178–222. [in Japanese].
Hirose S, Hamashima Y. Morphological observations on the vasculitis in the mucocutaneous lymph node syndrome. A skin biopsy study of 27 patients. Eur J Pediatr 1978; 129:17–27.
Yun SH, Yang NR, Park SA. Associated symptoms of Kawasaki disease. Korean Circ J 2011; 41:394–398.
Constantinescu CS. Migraine and Raynaud phenomenon: possible late complications of Kawasaki disease. Headache 2002; 42:227–229.
Savage CO, Winearls CG, Evans DJ, et al. Microscopic polyarteritis: presentation, pathology and prognosis. QJM 1985; 220:467–483.
Hagen EC, Daha MR, Hermans J, et al. Diagnostic value of standardized assays for antineutrophil cytoplasmic antibodies in idiopathic systemic vasculitis: EC/BCR Project for ANCA Assay Standardization. Kidney Int 1998; 53:743–753.
Drachman DA. Neurological complications of Wegener's granulomatosis. Arch Neurol 1963; 8:145–155.
Churg J, Strauss L. Allergic granulomatosis, allergic angiitis, and periarteritis nodosa. Am J Pathol 1951; 27:277–301.
North I, Strek ME, Leff AR. Churg-Strauss syndrome. Lancet 2003; 361:587–594.
Masi AT, Hunder GG, Lie JT, et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 1990; 33:1094–1100.
Hattori N, Ichimura M, Nagamatsu M, et al. Clinicopathological features of Churg-Strauss syndrome-associated neuropathy. Brain 1999; 122:427–439.
Ferri C, Sebastiani M, Giuggioli D, et al. Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients. Semin Arthritis Rheum 2004; 33:355–374.
Wintrobe MM, Buell MV. Hyperproteinemia associated with multiple myeloma. With report of a case in which an extraordinary hyperproteinemia was associated with thrombosis of the retinal veins and symptoms suggesting Raynauds disease. Bull Johns Hopkins Hosp 1933; 52:156–165.
Gorevic PD, Kassab HJ, Levo Y, et al. Mixed cryoglobulinemia: clinical aspects and long-term follow-up of 40 patients. Am J Med 1980; 69:287–308.
Brouet JC, Clauvel JP, Danon F, et al. Biologic and clinical significance of cryoglobulins: a report of 86 cases. Am J Med 1974; 57:775–788.
Origgi L, Vanoli M, Carbone A, et al. Central nervous system involvement in patients with HCV-related cryoglobulin. Am J Med Sci 1998; 315:208–210.
Cacoub P, Sbai A, Hausfater P, et al. Atteinte neurologique central et infection par le virus de l’hèpatite. Gastroenterol Clin Biol 1998; 22:631–633. [in French].
Petty GW, Duffy J, Huston J. Cerebral ischemic in patients with hepatitis C virus infection and mixed cryoglobulinemia. Mayo Clin Proc 1996; 71:671–678.
Díaz de Entre-Sotos FZ, Pérez-Aloe MT, Pérez-Tovar JF. Stroke and limb ischaemia in hepatitis C virus-related cryoglobulinaemia. Ir J Med Sci 2004; 173:57.
Ince PG, Duffey P, Cochrane HR, et al. Relapsing ischemic encephalopathy and cryoglobulinemia. Neurology 2000; 55:1579–1581.
Abramsky O, Slavin S. Neurological manifestations in patients with mixed cryoglobulinemia. Neurology 1974; 24:245–249.
Ramos-Cassals M, Robles A, Brito-Zeron P, et al. Life-threatening cryoglobulinemia: clinical and immunological characterization of 29 cases. Semin Arthritis Rheum 2006; 36:189–196.
Wisnieski JJ, Baer AN, Christensen J, et al. Hypocomplementemic urticarial vasculitis syndrome. Clinical and serological findings in 18 patients. Medicine 1995; 74:24–41.
Katsiari CG, Vikelis M, Paraskevopoulou ES, et al. Headache in systemic lupus erythematosus vs multiple sclerosis: a prospective comparative study. Headache 2011; 51:1398–1407.
Buck A, Christensen J, McCarty M. Hypocomplementemic urticarial vasculitis syndrome. A case report and literature review. J Clin Aesthet Dermatol 2012; 5:36–46.
Grotz W, Baba HA, Becker JU, et al. Hypocomplementemic urticarial vasculitis syndrome. Dtsch Arztebl Int 2009; 106:756–763.
Osler W. The visceral lesions of purpura and allied conditions. BMJ 1914; 1:517–525.
Green B. Schöenlein-Henoch purpura with blood in the cerebrospinal fluid. Br Med J 1946; 1:836.
Lewis IC, Philpott MG. Neurologic complications in the Schöenlein-Henoch purpura syndrome. Arch Dis Child 1956; 31:369–371.
Belman AL, Leicher CR, Moshe SL, et al. Neurologic manifestations of Schoenlein-Henoch purpura: report of three cases and review of the literature. Pediatrics 1985; 75:687–692.
Saulsbury FT. Clinical update: Henoch-Schönlein purpura. Lancet 2007; 369:976–978.
Trygstad CW, Stiehm ER. Elevated serum IgA globulin in anaphylactoid purpura. Pediatrics 1971; 47:1023–1028.
Levinsky RJ, Barratt TM. IgA immune complexes in Henoch-Schönlein purpura. Lancet 1979; 2:1100–1103.
Conley ME, Cooper MD, Michael AF. Selective deposition of immunoglobulin A 1 in immunoglobulin A nephropathy, anaphylactoid purpura nephritis, and systemic lupus erythematosus. J Clin Invest 1980; 66:1432–1436.
Behcet H, Matteson EL. On relapsing, aphthous ulcers of the mouth, eye and genitalia caused by a virus. Clin Exp Rheumatol 2010; 28:S2–S5.
Gökçay F, Celebisoy N, Gökçay A, et al. Neurological symptoms and signs in Behcet disease: a Western Turkey experience. Neurologist 2011; 17:147–150.
Wolf SM, Schotland DL, Phillips LL. Involvement of nervous system in Behçet's syndrome. Arch Neurol 1965; 12:315–325.
Saip S, Siva A, Altintas A, et al. Headache in Behçet's syndrome. Headache 2005; 45:911–919.
McMenemey WH, Lawrence TJ. Encephalomyelopathy in Behçet's disease. Report of necropsy findings in two cases. Lancet 1957; 273:353–358.
Rubinstein LJ, Urich H. Meningo-encephalitis of Behçet's disease. Case report with pathological findings. Brain 1963; 86:151–160.
Kawakita H, Nishimura M, Satoh Y, et al. Neurological aspects of Behçet's disease. A case report and clinico-pathological review of the literature in Japan. J Neurol Sci 1967; 5:417–439.
Arai Y, Kohno S, Takahashi Y, et al. Autopsy case of neuro-Behçet's disease with multifocal neutrophilic perivascular inflammation. Neuropathology 2006; 26:579–585.
Koseoglu E, Yildirim A, Borlu M. Is headache in Behçet's disease related to silent neurologic involvement? Clin Exp Rheumatol 2011; 29:S32–S37.
Siva A, Saip S. The spectrum of nervous system involvement in Behçet's syndrome and its differential diagnosis. J Neurol 2009; 256:513–529.
Hadfield MG, Aydin F, Lippman HR, et al. Neuro-Behçet's disease. Clin Neuropathol 1997; 16:55–60.
Mogan RF, Baumgarten CJ. Meniere's disease complicated by recurrent interstitial keratitis: excellent results following cervical ganglionectomy. West J Surg 1934; 42:628.
Cogan DG. Syndrome of nonsyphilitic interstitial keratitis and vestibuloauditory symptoms. Arch Ophthal 1945; 33:144–149.
Norton EW, Cogan DG. Syndrome of nonsyphylitic interstitial keratitis and vestibuloauditory symptoms. A long-term follow-up. Arch Ophthalmol 1959; 61:695–697.
Cody DT, Williams HL. Cogan's syndrome. Laryngoscope 1960; 70:447–478.
Cody DT, Williams HL. Cogan's syndrome. Proc Staff Meet Mayo Clin 1962; 37:372–375.
Gluth MB, Baratz KH, Matteson EL, et al. Cogan syndrome: a retrospective review of 60 patients throughout a half century. Mayo Clin Proc 2006; 81:483–488.
Pagnini I, Zannin ME, Vittadello F, et al. Clinical features and outcome of Cogan syndrome. J Pediatr 2012; 160:303–307.
Haynes BF, Kaiser-Kupfer MI, Mason P, et al. Cogan's syndrome: studies in thirteen patients, long-term follow-up, and a review of the literature. Medicine 1980; 59:426–441.
Fisher ER, Hellstrom HR. Cogan's syndrome and systemic vascular disease. Analysis of pathological features with reference to its relationship to thromboangiitis obliterans (Buerger). Arch Pathol 1961; 72:572–592.
Crawford WJ. Cogan's syndrome associated with polyarteritis nodosa. A report of three cases. Pa Med J 1957; 60:835–838.
Eisenstein B, Taubenhaus M. Nonsyphilitic interstitial keratitis and bilateral deafness (Cogan's syndrome) associated with cardiovascular disease. N Engl J Med 1958; 258:1074–1079.
Oliner L, Taubenhaus M, Shapira TM, et al. Nonsyphilitic interstitial keratitis and bilateral deafness (Cogan's syndrome) associated with essential polyangiitis (periarteritis nodosa). A review of the syndrome with consideration of a possible pathogenic mechanism. N Engl J Med 1953; 248:1001–1008.
Leff TL. Cogan's syndrome: ocular pathology. N Y State J Med 1967; 67:2249–2257.
Gelfand ML, Kantor T, Gorstein F. Cogan's syndrome with cardiovascular involvement: aortic insufficiency. Bull N Y Acad Med 1972; 48:647–660.
Cheson BD, Bluming AZ, Alroy J. Cogan's syndrome: a systemic vasculitis. Am J Med 1976; 60:549–555.
Del Caprio J, Espinozea LR, Osterland SK. Cogan's syndrome in HLA Bw 17. N Engl J Med 1976; 295:1262–1263.
Pinals RS. Cogan's syndrome with arthritis and aortic insufficiency. J Rheumatol 1978; 5:294–298.
Hernandez-Rodriguez J, Hoffman GS. Updating single-organ vasculitis. Curr Opin Rheumatol 2012; 24:38–45.
Klemperer P. Diseases of the collagen system. Bull N Y Acad Med 1947; 23:581–588.
Klemperer P. The pathogenesis of lupus erythematosus and allied conditions. Ann Intern Med 1948; 28:1–11.
Borowoy AM, Pope JE, Silverman E, et al. Neuropsychiatric lupus: the prevalence and autoantibody associations depend on the definition: results from the 100 Faces of Lupus Cohort. Semin Arthritis Rheum 2012; 42:179–185.
The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndrome. Arthritis Rheum 1999; 42:599–608.
Tomic-Lucic A, Petrovic R, Radak-Perovic M, et al. Late-onset systemic lupus erythematosus: clinical features, course, and prognosis. Clin Rheumatol 2013; 32:1053–1058.
Johnson RT, Richardson EP. The neurological manifestations of systemic lupus erythematosus. Medicine 1968; 47:337–369.
Estes D, Christian CL. The natural history of systemic lupus erythematosus by prospective analysis. Medicine 1971; 50:85–95.
Devinsky O, Petito CK, Alonso DR. Clinical and neuropathological findings in systemic lupus erythematosus: the role of vasculitis, heart emboli, and thrombotic thrombocytopenic purpura. Ann Neurol 1988; 23:380–384.
Feinglass EJ, Arnett FC, Dorsch CA, et al. Neuropsychiatric manifestations of systemic lupus erythematosus: diagnosis, clinical spectrum, and relationship to other features of the disease. Medicine 1976; 55:323–339.
Mintz G, Fraga A. Arteritis in systemic lupus erythematosus. Arch Intern Med 1965; 116:55–66.
Trevor RP, Sondheimer FK, Fessel WJ, et al. Angiographic demonstration of major cerebral vessel occlusion in systemic lupus erythematosus. Neuroradiology 1972; 4:202–207.
Younger DS, Sacco R, Levine SR, et al. Major cerebral vessel occlusion in SLE due to circulating anticardiolipin antibodies. Stroke 1994; 25:912–914.
Khamashta MA, Cervera R, Hughes GR. The central nervous system in systemic lupus erythematosus. Rheumatol Int 1991; 11:117–119.
Levine SR, Welch KM. The spectrum of neurologic disease associated with antiphospholipid antibodies. Arch Neurol 1987; 44:876–883.
McCaffrey LM, Petelin A, Cunha BA. Systemic lupus erythematosus (SLE) cerebritis versus Listeria monocytogenes meningoencephalitis in a patient with systemic lupus erythematosus on chronic corticosteroid therapy: the diagnostic importance of cerebrospinal fluid (CSF) of lactic acid levels. Heart Lung 2012; 41:394–397.
Aletaha D, Neogi T, Silman AJ. 2010 rheumatoid arthritis classification criteria. An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Arthritis Rheum 2010; 62:2569–2581.
Turesson C. Extra-articular rheumatoid arthritis. Curr Opin Rheumatol 2013; 25:360–366.
Voskuyl AE, Zwinderman AH, Westedt ML, et al. The mortality of rheumatoid vasculitis compared with rheumatoid arthritis. Arthritis Rheum 1996; 39:266–271.
Pirani CL, Bennett GA. Rheumatoid arthritis; a report of three cases progressing from childhood and emphasizing certain systemic manifestations. Bull Hosp Joint Dis 1951; 12:335–367.
Kemper JW, Baggenstoss AH, Slocumb C H. The relationship of therapy with cortisone to the incidence of vascular lesions in rheumatoid arthritis. Ann Intern Med 1957; 46:831–851.
Sokoloff L, Bunim JJ. Vascular lesions in rheumatoid arthritis. J Chronic Dis 1957; 5:668–687.
Johnson RL, Smyth CJ, Holt GW, et al. Steroid therapy and vascular lesions in rheumatoid arthritis. Arthritis Rheum 1959; 2:224–249.
Steiner JW, Gelbloom AJ. Intracranial manifestations in two cases of systemic rheumatoid disease. Arthritis Rheum 1959; 2:537–545.
Ouyang R, Mitchell DM, Rozdilsky B. Central nervous system involvement in rheumatoid disease. Neurology 1967; 17:1099–1105.
Ramos M, Mandybur TI. Cerebral vasculitis in rheumatoid arthritis. Arch Neurol 1975; 32:271–275.
Watson P, Fekete J, Deck J. Central nervous system vasculitis in rheumatoid arthritis. Can J Neurol Sci 1977; 4:269–272.
Westwell-Roper C, Lubieniecka JM, Brown KL, et al. Clinical practice variation and need for pediatric-specific treatment guidelines among rheumatologists caring for children with ANCA-associated vasculitis: an international clinician survey. Pediatr Rheumatol Online J 2017; 15:61.
Craven A, Robson J, Ponte C, et al. ACR/EULAR-endorsed study to develop Diagnostic and Classification Criteria for Vasculitis (DCVAS). Clin Exp Nephrol 2013; 17:619–621.
Cabral DA, Uribe AG, Benseler S, et al. Classification, presentation, and initial treatment of Wegener's granulomatosis in childhood. Arthritis Rheum 2009; 60:3413–3424.
Hellmich B, Agueda A, Monti S, et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 2020; 79:19–30.
Yates M, Loke YK, Watts RA, et al. Prednisolone combined with adjunctive immunosuppression is not superior to prednisolone alone in terms of efficacy and safety in giant cell arteritis: meta-analysis. Clin Rheumatol 2014; 33:227–236.
Chandran A, Udayakumar PD, Kermani TA, et al. Glucocorticoid usage in giant cell arteritis over six decades (1950 to 2009). Clin Exp Rheumatol 2015; 33:S-98-102.
Boureau AS, Faucal Pd, Espitia O, et al. Utilisation de l’azathioprine dans le traitement de l’artérite à cellules géantes [Place of azathioprine in the treatment of giant cell arteritis]. Rev Med Interne 2016; 37:723–729.
Spiera RF, Mitnick HJ, Kupersmith M, et al. A prospective, double-blind, randomized, placebo-controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). Clin Exp Rheumatol 2001; 19:495–501.
Jover JA, Hernandez-Garcia C, Morado IC, et al. Combined treatment of giant-cell arteritis with methotrexate and prednisone. a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001; 134:106–114.
Hoffman GS, Cid MC, Hellmann DB, et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum 2002; 46:1309–1318.
Hoffman GS, Cid MC, Rendt-Zagar KE, et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med 2007; 146:621–630.
Sciascia S, Piras D, Baldovino S, et al. Mycophenolate mofetil as steroid-sparing treatment for elderly patients with giant cell arteritis: report of three cases. Aging Clin Exp Res 2012; 24:273–277.
Shirai T, Sato H, Fujii H, et al. The feasible maintenance dose of corticosteroid in Takayasu arteritis in the era of biologic therapy. Scand J Rheumatol 2021; 50:462–468.
Ohigashi H, Haraguchi G, Konishi M, et al. Improved prognosis of Takayasu arteritis over the past decade—comprehensive analysis of 106 patients. Circ J 2012; 76:1004–1011.
Kamisawa T, Okazaki K, Kawa S, et al. Japanese consensus guidelines for management of autoimmune pancreatitis: III. Treatment and prognosis of AIP. J Gastroenterol 2010; 45:471–477.
Campochiaro C, Tomelleri A, Sartorelli S, et al. A Prospective Observational Study on the Efficacy and Safety of Infliximab-Biosimilar (CT-P13) in Patients With Takayasu Arteritis (TAKASIM). Front Med (Lausanne) 2021; 8:723506.
Regola F, Uzzo M, Toniati P, et al. Novel therapies in Takayasu arteritis. Front Med (Lausanne) 2012; 8:814075.
Nakaoka Y, Isobe M, Tanaka Y, et al. Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study. Rheumatology (Oxford) 2020; 59:2427–2434.
Salvarani C, Hatemi G. Management of large-vessel vasculitis. Curr Opin Rheumatol 2019; 31:25–31.
Terrier B, Darbon R, Durel CA, et al. French recommendations for the management of systemic necrotizing vasculitides (polyarteritis nodosa and ANCA-associated vasculitides). Orphanet J Rare Dis 2020; 15:351.
Guillevin L, Cohen P, Mahr A, et al. Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: a prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients. Arthritis Rheum 2003; 49:93–100.
Erden A, Batu ED, Sonmez HE, et al. Comparing polyarteritis nodosa in children and adults: a single center study. Int J Rheum Dis 2017; 20:1016–1022.
Brogan PA, Arch B, Hickey H, et al. Mycophenolate mofetil versus cyclophosphamide for remission induction in childhood polyarteritis nodosa: an open-label, randomized, bayesian noninferiority trial. Arthritis Rheumatol 2021; 73:1673–1682.
Ginsberg S, Rosner I, Slobodin G, et al. Infliximab for the treatment of refractory polyarteritis nodosa. Clin Rheumatol 2019; 38:2825–2833.
Regent A, Mouthon L, Guillevin L, et al. Role of therapeutic plasma exchanges in systemic vasculitis. Transfus Apher Sci 2020; 59:102992.
de Graeff N, Groot N, Ozen S, et al. European consensus-based recommendations for the diagnosis and treatment of Kawasaki disease – the SHARE initiative. Rheumatology (Oxford) 2019; 58:672–682.
Durongpisitkul K, Gururaj VJ, Park JM, et al. The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment. Pediatrics 1995; 96:1057–1061.
Furukawa T, Kishiro M, Akimoto K, et al. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease. Arch Dis Child 2008; 93:142–146.
Newburger JW, Sleeper LA, McCrindle BW, et al. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. N Engl J Med 2007; 356:663–675.
Yates M, Watts RA, Bajema IM, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis 2016; 75:1583–1594.
Pagnoux C, Guillevin L. Treatment of granulomatosis with polyangiitis (Wegener's). Expert Rev Clin Immunol 2015; 11:339–348.
Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992; 116:488–498.
Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010; 363:221–232.
Jones RB, Tervaert JW, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010; 363:211–220.
Jayne D. Rituximab for ANCA-associated vasculitis: the UK experience. Presse Med 2013; 42:532–534.
Charles P, Guillevin L. Rituximab for ANCA-associated vasculitides: the French experience. Presse Med 2013; 42:534–536.
Han F, Liu G, Zhang X, et al. Effects of mycophenolate mofetil combined with corticosteroids for induction therapy of microscopic polyangiitis. Am J Nephrol 2011; 33:185–192.
Silva F, Specks U, Kalra S, et al. Mycophenolate mofetil for induction and maintenance of remission in microscopic polyangiitis with mild to moderate renal involvement—a prospective, open-label pilot trial. Clin J Am Soc Nephrol 2010; 5:445–453.
Specks U, Merkel PA, Seo P, et al. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med 2013; 369:417–427.
Benard V, Farhat C, Zarandi-Nowroozi M, et al. Comparison of two rituximab induction regimens for antineutrophil cytoplasm antibody-associated vasculitis: systematic review and meta-analysis. ACR Open Rheumatol 2021; 3:484–494.
Cartin-Ceba R, Golbin JM, Keogh KA, et al. Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a single center. Arthritis Rheum 2012; 64:3770–3778.
Smith RM, Jones RB, Guerry MJ, et al. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2012; 64:3760–3769.
De Groot K, Rasmussen N, Bacon PA, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005; 52:2461–2469.
Gopaluni S, Smith RM, Lewin M, et al. Rituximab versus azathioprine as therapy for maintenance of remission for antineutrophil cytoplasm antibody-associated vasculitis (RITAZAREM): study protocol for a randomized controlled trial. Trials 2017; 18:112.
Pagnoux C, Mahr A, Hamidou MA, et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med 2008; 359:2790–2803.
Hiemstra TF, Walsh M, Mahr A, et al. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. JAMA 2010; 304:2381–2388.
Jayne DR, Gaskin G, Rasmussen N, et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 2007; 18:2180–2188.
Walsh M, Merkel PA, Peh CA, et al. Plasma exchange and glucocorticoid dosing in the treatment of antineutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial. Trials 2013; 14:73.
Jayne DR, Chapel H, Adu D, et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM 2000; 93:433–439.
Groh M, Pagnoux C, Baldini C, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. Eur J Intern Med 2015; 26:545–553.
Raffray L, Guillevin L. Updates for the treatment of EGPA. Presse Med 2020; 49:104036.
Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 2014; 371:1189–1197.
Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 2014; 371:1198–1207.
Jariwala M, Laxer RM. Childhood GPA, EGPA, and MPA. Clin Immunol 2020;211:108325.
Calatroni M, Consonni F, Allinovi M, et al. Prognostic factors and long-term outcome with ANCA-associated kidney vasculitis in childhood. Clin J Am Soc Nephrol 2021; 16:1043–1051.
Morishita KA, Moorthy LN, Lubieniecka JM, et al. Early outcomes in children with antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol 2017; 69:1470–1479.
Perez-Alamino R, Espinoza LR. Noninfectious cryoglobulinemia vasculitis (CryoVas): update on clinical and therapeutic approach. Curr Rheumatol Rep 2014; 16:420.
De Vita S, Quartuccio L, Isola M, et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum 2012; 64:843–853.
Sneller MC, Hu Z, Langford CA. A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis. Arthritis Rheum 2012; 64:835–842.
Lesniak K, Rymarz A, Lubas A, et al. Noninfectious, severe cryoglobulinemic vasculitis with renal involvement – safety and efficacy of long-term treatment with rituximab. Int J Nephrol Renovasc Dis 2012; 14:267–277.
Terrier B, Marie I, Lacraz A, et al. Non-HCV-related infectious cryoglobulinemia vasculitis: results from the French nationwide CryoVas survey and systematic review of the literature. J Autoimmun 2015; 65:74–81.
Saadoun D, Ghembaza A, Riviere S, et al. Rituximab plus belimumab in noninfectious refractory cryoglobulinemia vasculitis: a pilot study. J Autoimmun 2021; 116:102577.
Ferri C, Cacoub P, Mazzaro C, et al. Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature. Autoimmun Rev 2011; 11:48–55.
Ozen S, Marks SD, Brogan P, et al. European consensus-based recommendations for diagnosis and treatment of immunoglobulin A vasculitis-the SHARE initiative. Rheumatology (Oxford) 2019; 58:1607–1616.
Weiss PF, Feinstein JA, Luan X, et al. Effects of corticosteroid on Henoch-Schonlein purpura: a systematic review. Pediatrics 2007; 120:1079–1087.
Hernandez-Rodriguez J, Carbonell C, Miron-Canelo JA, et al. Rituximab treatment for IgA vasculitis: a systematic review. Autoimmun Rev 2020; 19:102490.
Ren P, Han F, Chen L, et al. The combination of mycophenolate mofetil with corticosteroids induces remission of Henoch-Schonlein purpura nephritis. Am J Nephrol 2012; 36:271–277.
Nikibakhsh AA, Mahmoodzadeh H, Karamyyar M, et al. Treatment of severe Henoch-Schonlein purpura nephritis with mycophenolate mofetil. Saudi J Kidney Dis Transpl 2014; 25:858–863.
Jachiet M, Flageul B, Deroux A, et al. The clinical spectrum and therapeutic management of hypocomplementemic urticarial vasculitis: data from a French nationwide study of fifty-seven patients. Arthritis Rheumatol 2015; 67:527–534.
Navarro-Navarro I, Jimenez-Gallo D, Villegas-Romero I, et al. Use of omalizumab in the treatment of hypocomplementemic urticarial vasculitis. Dermatol Ther 2020; 33:e13237.
Noel N, Wechsler B, Boutin DLTH, et al. Outcome of neuro-Behçet: analysis of a large cohort. La Presse Medicale 2013; 42:692.
Shugaiv E, Tuzun E, Mutlu M, et al. Mycophenolate mofetil as a novel immunosuppressant in the treatment of neuro-Behçet's disease with parenchymal involvement: presentation of four cases. Clin Exp Rheumatol 2011; 29:S64–67.
Hatemi G, Merkel PA, Hamuryudan V, et al. Outcome measures used in clinical trials for Behcet syndrome: a systematic review. J Rheumatol 2014; 41:599–612.
Nanthapisal S, Eleftheriou D, Hong Y, et al. Behçet disease in children: the Great Ormond Street Hospital experience. Presse Med 2013; 42:651.
Karadeniz H, Vaglio A. IgG4-related disease: a contemporary review. Turk J Med Sci 2020; 50 (si-2):1616–1631.
Puéchal X, Gottenberg JE, Berthelot JM, et al. Rituximab therapy for systemic vasculitis associated with rheumatoid arthritis: results from the autoimmunity and rituximab registry. Arthritis Care Res 2012; 64:331–339.
Buch MH, Smolen JS, Betteridge N, et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2011; 70:909–920.
Bartolucci P, Ramanoelina J, Cohen P, et al. Efficacy of the anti-TNF-α antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology 2002; 41:1126–1132.
Puéchal X, Miceli-Richard C, Mejjad O, et al. Antitumor necrosis factor treatment in patients with refractory systemic vasculitis associated with rheumatoid arthritis. Ann Rheum Dis 2008; 67:880–884.
Puéchal X. Rheumatoid arthritis vasculitis. Presse Med 2013; 42:527–530.